Publication | Closed Access

A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity

Improved Anticancer ActivityEgfr-lytic Hybrid PeptideMedicinePeptide LibraryCancer GrowthPeptide TherapeuticPeptide SynthesisAnti-cancer AgentSingle ReplacementPharmacologyRadiation OncologyCancer ResearchTumor MicroenvironmentTumor BiologyDrug Discovery